Thomas W. Dubensky

Thomas W. Dubensky

Company: Tempest Therapeutics

Job title: President


Breakfast Panel: Dissecting the Recent Clinical Trial Failures & Experience Gained 9:00 am

Understanding the challenges and how these can be overcome in future Discussing target engagement and response biomarkers Exploring similarities between trial design in preclinical vs clinical settings Debating the reliability of current biomarkers Understanding the design, translation and execution in response assessments Determining “how much PRR activation, is too much” in patients given that most…Read more

day: Day Two

Systemic Small Molecule TREX1 Inhibitors to Selectively Activate STING in the TME of Metastatic Disease 11:00 am

Although STING is a critical innate immune receptor, the clinical activity of STING agonists given by intratumoral administration has not compared well to preclinical studies TREX1 is a cytosolic dsDNA exonuclease that modulates the cGAS/STING pathway activation, is a DNA repair enzyme, is upregulated in tumors, and is a target to preferentially activate the STING…Read more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.